Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | IMO-2125 |
| Trade Name | |
| Synonyms | Tilsotolimod |
| Drug Descriptions |
Tilsotolimod (IMO-2125) is an immunomodulatory oligonucleotide (IMO) that targets toll-like receptor 9 (TLR9), resulting in activation of anti-tumor immunity (PMID: 23207140, PMID: 29956749). |
| DrugClasses | TLR9 Agonist 9 |
| CAS Registry Number | 2089768-67-0 |
| NCIT ID | C125080 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ABBV-368 + Budigalimab + IMO-2125 + Nab-paclitaxel | ABBV-368 Budigalimab IMO-2125 Nab-paclitaxel | 0 | 1 |
| ABBV-368 + IMO-2125 | ABBV-368 IMO-2125 | 0 | 1 |
| ABBV-368 + IMO-2125 + Nab-paclitaxel | ABBV-368 IMO-2125 Nab-paclitaxel | 0 | 1 |
| IMO-2125 | IMO-2125 | 0 | 2 |
| IMO-2125 + Ipilimumab | IMO-2125 Ipilimumab | 0 | 2 |
| IMO-2125 + Ipilimumab + Nivolumab | IMO-2125 Ipilimumab Nivolumab | 0 | 2 |
| IMO-2125 + Nivolumab | IMO-2125 Nivolumab | 0 | 1 |
| IMO-2125 + Pembrolizumab | IMO-2125 Pembrolizumab | 0 | 1 |